All Updates

All Updates

icon
Filter
Funding
Marea Therapeutics raises USD 190 million in Series A and B funding to develop cardiometabolic candidate
Precision Medicine
Jun 18, 2024
This week:
Partnerships
MGI Tech and Predica Diagnostics collaborate to develop Predica's targeted RNA sequencing tests
Precision Medicine
Jul 11, 2024
Partnerships
Renalytix partners with Steno Diabetes Center to advance precision medicine solutions for diabetes and chronic kidney disease
Precision Medicine
Jul 11, 2024
Partnerships
Myriad Genetics and Personalis cross-license patents for tumor-informed cancer treatment tests
Precision Medicine
Jul 11, 2024
Funding
Element Biosciences raises USD 277 million in Series D funding to commercialize AVITI DNA sequencer and support AVITI24 launch
Precision Medicine
Jul 11, 2024
Funding
Jacobi Robotics raises USD 5 million in seed funding to expand capacity
Smart Factory
Jul 11, 2024
M&A
Formlabs acquires Micronics for undisclosed sum to develop next-generation SLS printers
Additive Manufacturing
Jul 11, 2024
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Jul 11, 2024
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Jul 11, 2024
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Jul 11, 2024
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Jul 11, 2024
Precision Medicine

Precision Medicine

Jun 18, 2024

Marea Therapeutics raises USD 190 million in Series A and B funding to develop cardiometabolic candidate

Funding

  • Marea Therapeutics has raised USD 190 million in Series A and B rounds led by Third Rock Ventures and Sofinnova Investments, respectively. Other investors include Forbion, Perceptive Xontogeny Venture Fund, venBio, Alpha Wave Global, Omega Funds, and Surveyor Capital.

  • The funds acquired will be used to develop the company’s MAR001 Phase II program, which is indicated for cardiometabolic diseases, and to progress extra pipeline programs.

  • Marea Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing small molecules to treat cardiology and blood-related conditions. Its lead candidate, MAR-001, targets ANGPTL4, a protein highly expressed in adipose tissue, potentially providing a novel method of treatment for cardiometabolic diseases. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.